Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity
Cannabis & Cannabinoid Research · 01.08.2023 · 8 (4) · 623-633
DOI: 10.1089/can.2022.0077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.08.2023. Verfasst von Liad Hinden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Obesity and Metabolism Laboratory, Department of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusale…. Hauptthemen laut MEDLINE: Cystitis, Cannabinoids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The endocannabinoid system (ECS) plays a key physiological role in bladder function and it has been suggested as a potential target for relieving lower urinary tract symptoms (LUTSs). Whereas most studies indicate that activating the ECS has some beneficial effects on the bladder, some studies imply the opposite. In this study, we investigated the therapeutic potential of peripheral cannabinoid-1 receptor (CB 1 R) blockade in a mouse model for LUTSs. Materials and Methods: To this end, we used the cyclophosphamide (CYP; 300 mg/kg, intraperitoneal)-induced cystitis model of bladder dysfunction, in which 12-week-old, female C57BL/6 mice were treated with the peripherally restricted CB 1 R antagonist, JD5037 (3 mg/kg), or vehicle for three consecutive days. Bladder dysfunction was assessed using the noninvasive voiding spot assay (VSA) as well as the bladder-to-body weight (BW) ratio and gene and protein expression levels; ECS tone was assessed at the end of the study.
Results
Peripheral CB 1 R blockade significantly ameliorated the severity of CYP-induced cystitis, manifested by reduced urination events measured in the VSA and an increased bladder-to-BW ratio. Moreover, JD5037 normalized CYP-mediated bladder ECS tone imbalance by affecting both the expression of CB 1 R and the endocannabinoid levels. These effects were associated with the ability of JD5037 to reduce CYP-induced inflammatory response, manifested by a reduction in levels of the proinflammatory cytokine, tumor necrosis factor alpha (TNFα), in the bladder and serum.
Conclusions
Collectively, our results highlight the therapeutic relevance of peripheral CB 1 R blockade in ameliorating CYP-induced cystitis; they may further support the preclinical development and clinical use of peripherally restricted CB 1 R antagonism for treatment of LUTSs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obesity and Metabolism Laboratory, Department of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Urology Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- In partial fulfillment of MD requirements, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
ORCID-Profile: Liad Hinden
Zitieren
APA
Hinden, L., Ludyansky, R., Leidershnaider, S., Harris, Y., Nemirovski, A., Gofrit, O. N., Tam, J., & Hidas, G. (2023). Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity. Cannabis & Cannabinoid Research, 8(4), 623-633. https://doi.org/10.1089/can.2022.0077
Vancouver
Hinden L, Ludyansky R, Leidershnaider S, Harris Y, Nemirovski A, Gofrit ON, et al. Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity. Cannabis & Cannabinoid Research. 2023;8(4):623-633. doi:10.1089/can.2022.0077
BibTeX
@article{Hinden2023,
author = {Hinden, Liad and Ludyansky, Rami and Leidershnaider, Sary and Harris, Yoav and Nemirovski, Alina and Gofrit, Ofer N and Tam, Joseph and Hidas, Guy},
title = {Peripheral Cannabinoid-1 Receptor Blockade Ameliorates Cystitis Severity},
journal = {Cannabis & Cannabinoid Research},
year = {2023},
volume = {8},
number = {4},
pages = {623--633},
doi = {10.1089/can.2022.0077}
}
EUVIMED